Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain.

Pérez C, Navarro A, Saldaña MT, Figueras-Balsells M, Muñoz-Tudurí M, Rejas J.

Clin J Pain. 2013 Jun;29(6):471-7. doi: 10.1097/AJP.0b013e3182652c2b.

PMID:
23328322
[PubMed - indexed for MEDLINE]
2.

A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.

de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, Rejas J.

Pain Med. 2012 May;13(5):699-710. doi: 10.1111/j.1526-4637.2012.01375.x.

PMID:
22594706
[PubMed - indexed for MEDLINE]
3.

Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.

Navarro A, Saldaña MT, Pérez C, Masramón X, Rejas J.

Pain Pract. 2012 Jun;12(5):382-93. doi: 10.1111/j.1533-2500.2011.00515.x. Epub 2011 Oct 18.

PMID:
22004531
[PubMed - indexed for MEDLINE]
4.

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.

Pérez C, Navarro A, Saldaña MT, Masramón X, Rejas J.

Clin Ther. 2010 Jul;32(7):1357-70. doi: 10.1016/j.clinthera.2010.07.014.

PMID:
20678683
[PubMed - indexed for MEDLINE]
5.

A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.

Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.

BMC Neurol. 2011 Jan 20;11:7. doi: 10.1186/1471-2377-11-7.

PMID:
21251268
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A cost-consequence analysis of pregabalin versus usual care in the symptomatic treatment of refractory low back pain: sub-analysis of observational trial data from orthopaedic surgery and rehabilitation clinics.

Morera-Domínguez C, Ceberio-Balda F, Flórez-García M, Masramón X, López-Gómez V.

Clin Drug Investig. 2010;30(8):517-31. doi: 10.2165/11536280-000000000-00000.

PMID:
20513162
[PubMed - indexed for MEDLINE]
7.

Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice.

Saldaña MT, Pérez C, Navarro A, Masramón X, Rejas J.

Clin Drug Investig. 2012 Jun 1;32(6):401-12. doi: 10.2165/11599400-000000000-00000.

PMID:
22480279
[PubMed - indexed for MEDLINE]
8.

Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.

Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Planas-Comes A.

J Eval Clin Pract. 2012 Dec;18(6):1170-9. doi: 10.1111/j.1365-2753.2011.01752.x. Epub 2011 Aug 30.

PMID:
21883712
[PubMed - indexed for MEDLINE]
9.

An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.

de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, González-Gómez FJ, Ruiz L, Rejas J.

Prim Care Diabetes. 2012 Dec;6(4):303-12. doi: 10.1016/j.pcd.2012.03.001. Epub 2012 May 15.

PMID:
22595032
[PubMed - indexed for MEDLINE]
10.

Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain.

Pérez C, Navarro A, Saldaña MT, Masramón X, Pérez M, Rejas J.

Pain Med. 2013 Dec;14(12):1954-63. doi: 10.1111/pme.12276. Epub 2013 Oct 30.

PMID:
24330229
[PubMed - indexed for MEDLINE]
11.

A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish setting.

Prettyjohns M, Sandelin R, Lister S, Norrefalk JR.

J Med Econ. 2012;15(6):1097-109. doi: 10.3111/13696998.2012.704458. Epub 2012 Jul 5.

PMID:
22712872
[PubMed - indexed for MEDLINE]
12.

Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.

Zhao Y, Sun P, Watson P.

Curr Med Res Opin. 2011 Apr;27(4):785-92. doi: 10.1185/03007995.2011.554807. Epub 2011 Feb 8.

PMID:
21303196
[PubMed - indexed for MEDLINE]
13.

Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.

Chevalier P, Lamotte M, Van Campenhout H, Eyckerman R, Annemans L.

J Med Econ. 2013;16(5):596-605. doi: 10.3111/13696998.2013.773333. Epub 2013 Mar 4.

PMID:
23409950
[PubMed - indexed for MEDLINE]
14.

Effect of pregabalin in the treatment of refractory neck pain: cost and clinical evidence from medical practice in orthopedic surgery and rehabilitation clinics.

Flórez-García M, Ceberio-Balda F, Morera-Domínguez C, Masramón X, Pérez M.

Pain Pract. 2011 Jul-Aug;11(4):369-80. doi: 10.1111/j.1533-2500.2010.00430.x. Epub 2010 Dec 29.

PMID:
21199310
[PubMed - indexed for MEDLINE]
15.

Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings.

Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.

Pain Med. 2010 May;11(5):719-31. doi: 10.1111/j.1526-4637.2010.00824.x. Epub 2010 Mar 22.

PMID:
20345618
[PubMed - indexed for MEDLINE]
16.

A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain.

Annemans L, Caekelbergh K, Morlion B, Hans G, De Cock P, Marbaix S.

Acta Clin Belg. 2008 May-Jun;63(3):170-8.

PMID:
18714847
[PubMed - indexed for MEDLINE]
17.

A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America.

Xochilcal-Morales M, Castro EM, Guajardo-Rosas J, Obregón TN, Acevedo JC, Chucan JM, Plancarte-Sanchez R, Davila G, Wajsbrot D, Guerrero M, Vinueza R.

Int J Clin Pract. 2010 Aug;64(9):1301-9. doi: 10.1111/j.1742-1241.2010.02389.x. Epub 2010 May 10.

PMID:
20487048
[PubMed - indexed for MEDLINE]
18.

Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.

Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C.

Clin Ther. 2006 Nov;28(11):1922-34.

PMID:
17213013
[PubMed - indexed for MEDLINE]
19.

Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.

Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP.

Clin Drug Investig. 2008;28(9):583-601.

PMID:
18666805
[PubMed - indexed for MEDLINE]
20.

PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial.

Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, Harris I, Day RO, Pik J, Jan S, Billot L, Lin CW.

Trials. 2013 Jul 11;14:213. doi: 10.1186/1745-6215-14-213.

PMID:
23845078
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk